Site Editor

Thomas Flaig, MD

Advertisement
Advertisement

Targeted PD-L1 Therapy for Bladder Cancer: View From the Middle East

By: Joshua Swore, PhD
Posted: Monday, January 9, 2023

The use of anti–PD-L1 therapy for patients with bladder cancer may serve as a beneficial therapeutic alternative, since 44.4% of bladder cancers in a study from the Middle East were found to be positive for PD-L1. Additional efforts should be targeted at investigating the efficacy of this treatment strategy, given the association between tumor grade and PD-L1 expression, explained Safia Al Nabhani, MD, of the Oman Medical Specialty Board, Muscat, Oman, and colleagues. These findings were published in the Oman Medical Journal.

From 2006 to 2017, a total of 68 patients with bladder cancer were recruited for the study from Sultan Qaboos University Hospital, Seeb, Oman. Most patients had either stage II (32.8%) or stage II (38.8%) cancer. A total of 79.4% of these cancers were classified as invasive urothelial carcinoma, and 83.8% of patients had high-grade tumors. Tissue samples were collected from patients and subjected to immunohistochemical analysis to assess PD-L1 expression by tumor cells. To assess PD-L1–positive expression in tumor cells via membrane or cytoplasmic staining, cutoff values of 5% and 25% were selected.

The study findings revealed that 44.4% of patients had PD-L1–positive tumors when the cutoff value was 5%. In addition, a significant association was identified between PD-L1 and tumor grade. However, no significant associations between PD-L1 expression and overall patient outcomes were noted. When the cutoff value was set to 25%, just 30.2% of the tumors were PD-L1–positive. Moreover, there was no significant association identified between PD-L1 expression and both tumor grade and overall patient outcomes.

Disclosure: The study authors reported no conflicts of interest.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.